DECLARATION UNDER SUBSECTION 196B(6)
OF THE VETERANS’ ENTITLEMENTS ACT 1986
The Repatriation Medical Authority (the Authority), under subsection 196B(6) of the Veterans' Entitlements Act 1986 (the Act), makes the following declaration in respect of the investigation concerning chemically-acquired brain injury caused by mefloquine, tafenoquine or primaquine notified in the Commonwealth of Australia Gazette of 14 February 2017.
The Authority declares that it does not propose to make a Statement of Principles concerning chemically-acquired brain injury caused by mefloquine, tafenoquine or primaquine, for the purposes of subsection 196B(2) or (3) of the Act. The Authority is of the view that there is insufficient sound medical-scientific evidence that exposure to mefloquine, tafenoquine or primaquine causes chronic brain injury. Further, there is insufficient sound medical-scientific evidence that there is a characteristic and persistent pattern of signs and symptoms following exposure to mefloquine, tafenoquine or primaquine that could be determined to be a particular kind of disease of, or injury to, the brain.
The Common Seal of the ) Repatriation Medical Authority ) was affixed at the direction of: ) | |
| PROFESSOR NICHOLAS SAUNDERS AO CHAIRPERSON 18 / 08 / 2017 |
Overview
The Veterans' Entitlements Act 1986 was enacted to provide a framework for the recognition and compensation of veterans' health conditions and disabilities. This Act serves to address the gaps in providing appropriate medical and financial support to veterans who have suffered from various health issues related to their service. Enacted by the Parliament of Australia, the policy objective of this Act is to ensure that veterans receive the necessary care and compensation for service-related health issues. In the context of chemically-acquired brain injuries, the Act allows for the consideration and declaration of Statements of Principles regarding specific conditions, which can lead to the recognition and compensation of affected veterans.
The Repatriation Medical Authority, under subsection 196B(6) of the Veterans' Entitlements Act 1986, has made a declaration regarding the investigation into chemically-acquired brain injury caused by mefloquine, tafenoquine, or primaquine. The Authority has determined that there is insufficient sound medical-scientific evidence to establish a link between exposure to these chemicals and chronic brain injury or a characteristic pattern of signs and symptoms. Consequently, the Authority does not propose to make a Statement of Principles concerning these injuries, reflecting the current state of medical-scientific evidence and the legislative process for recognising new veteran health issues.
Scope and Application
The Veterans’ Entitlements Act 1986 applies to veterans and their dependents who may be entitled to certain benefits and payments due to their service in the Australian Defence Force. This Act is a Commonwealth legislation, thus its application is national across Australia, encompassing all states and territories. The Act’s scope includes the provision of medical care, pensions, and other support services to veterans, contingent on their eligibility based on the nature and duration of their service. However, the application of the Act can be influenced by subordinate instruments, which may extend or restrict its provisions to specific circumstances or conditions. In the case of the declaration under subsection 196B(6) regarding chemically-acquired brain injury caused by mefloquine, tafenoquine, or primaquine, the Authority has determined that there is insufficient sound medical-scientific evidence to support a Statement of Principles for these conditions. This decision directly impacts veterans who may have claimed benefits related to these specific injuries, effectively excluding such claims under the Act unless new evidence emerges in the future.
Key Provisions
The Repatriation Medical Authority (the Authority) has declared under subsection 196B(6) of the Veterans' Entitlements Act 1986 (the Act) that it does not propose to make a Statement of Principles concerning chemically-acquired brain injury caused by mefloquine, tafenoquine, or primaquine. This declaration (subsection 196B(6)) was made in response to an investigation notified in the Commonwealth of Australia Gazette on 14 February 2017. The Authority has determined that there is insufficient sound medical-scientific evidence to support the connection between exposure to these chemicals and chronic brain injury, or a characteristic and persistent pattern of signs and symptoms that could be classified as a specific brain disease or injury. This decision is based on the lack of adequate evidence that would allow for a definitive statement under the Act.
The obligations and requirements imposed by this declaration include a thorough evaluation of available medical-scientific evidence. The Authority must ensure that all evidence considered is sound and sufficient to support a Statement of Principles. This involves assessing the nature and quality of scientific studies, expert opinions, and other relevant data that pertain to the potential link between exposure to mefloquine, tafenoquine, or primaquine and brain injury. The Authority is also required to make its findings publicly known through the Gazette, providing transparency and accountability in its decision-making process.
There are no explicit offences, penalties, or civil/criminal consequences mentioned in this declaration for breach of the Act. However, the implications of the Authority's decision can affect veterans and their families who may have been seeking recognition and support for their conditions. The Authority’s role is to provide a clear and evidence-based stance on the matter, which guides the provision of benefits and entitlements under the Act. The absence of a Statement of Principles may affect the eligibility of affected individuals for certain benefits, highlighting the importance of the Authority’s decision-making process.